Arena Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ARNA)

$39.97 -0.88 (-2.15 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$39.97
Today's Range$38.51 - $41.00
52-Week Range$11.30 - $42.74
Volume670,470 shs
Average Volume516,705 shs
Market Capitalization$1.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64

About Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals logoArena Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn's disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).

Receive ARNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ARNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ARNA
CUSIP04004710
Phone858-453-7200

Debt

Debt-to-Equity Ratio0.27%
Current Ratio4.42%
Quick Ratio4.32%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$123.97 million
Price / Sales12.66
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book24.08

Profitability

Trailing EPS($0.93)
Net Income$-22,510,000.00
Net Margins-36.78%
Return on Equity-34.12%
Return on Assets-14.83%

Miscellaneous

Employees106
Outstanding Shares39,260,000

Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions

What is Arena Pharmaceuticals' stock symbol?

Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."

When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?

Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Arena Pharmaceuticals' earnings last quarter?

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) released its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.65) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.66) by $0.01. The biopharmaceutical company had revenue of $7.95 million for the quarter, compared to analysts' expectations of $5.48 million. Arena Pharmaceuticals had a negative return on equity of 34.12% and a negative net margin of 36.78%. The firm's quarterly revenue was down 58.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.05) earnings per share. View Arena Pharmaceuticals' Earnings History.

When will Arena Pharmaceuticals make its next earnings announcement?

Arena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Arena Pharmaceuticals.

Where is Arena Pharmaceuticals' stock going? Where will Arena Pharmaceuticals' stock price be in 2018?

8 equities research analysts have issued 1-year price objectives for Arena Pharmaceuticals' shares. Their forecasts range from $19.00 to $63.00. On average, they expect Arena Pharmaceuticals' share price to reach $46.29 in the next twelve months. View Analyst Ratings for Arena Pharmaceuticals.

What are Wall Street analysts saying about Arena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "KOL event could fill in some important blank spaces. ARNA will host a lunch event on January 29 (12:30-1:30 pm) in NYC with two physician consultants to discuss modulators of S1P receptors and etrasimod, specifically. We believe the event could be helpful for investors as it relates to understanding important pharmacokinetic and pharmacodynamic properties of the drug candidate that we highlighted in a recent research report (here)." (1/17/2018)
  • 2. According to Zacks Investment Research, "Arena’s only approved product is Belviq, used for chronic weight management. Though it was the first obesity drug to be approved by the FDA in over a decade, is yet to impress with its performance. Moreover, Arena’s pipeline consists of early-to-mid stage candidates, still several years from commercialization. Plus, competition remains intense in the obesity market with both branded and generic players. However, the company’s partnership agreements and efforts to improve the performance of the drug are impressive. We are also encouraged by the company’s cost-reduction initiatives to streamline the organization to support its development programs. Shares of the company have outperformed the industry in the last one year." (1/10/2018)
  • 3. Needham & Company LLC analysts commented, "Arena mgmt hosted a conference call yesterday to provide a 2Q17 quarterly corporate update. Company announced positive results from a 61-pt Phase 2 trial of ralinepag in Pulmonary Arterial Hypertension (PAH) in Jul 2017. We await insight into FDA and EMA requirements for registration. Mgmt is not providing specific guidance, but we assume mtgs can be scheduled by YE17. Other upcoming milestones include top-line results from Phase 2 trials of etrasimod in Ulcerative Colitis (YE17) and APD-371 in pain associated with Crohn’s Disease (YE17)." (8/8/2017)

Who are some of Arena Pharmaceuticals' key competitors?

Who are Arena Pharmaceuticals' key executives?

Arena Pharmaceuticals' management team includes the folowing people:

  • Tina Susan Nova Ph.D., Independent Chairman of the Board (Age 63)
  • Amit D. Munshi, President, Chief Executive Officer, Director (Age 49)
  • Kevin R. Lind, Chief Financial Officer, Executive Vice President (Age 41)
  • Steven W. Spector J.D., Executive Vice President, General Counsel, Secretary (Age 52)
  • Vincent Aurentz, Executive Vice President and Chief Business Officer (Age 49)
  • Preston S. Klassen M.D., Executive Vice President - Research & Development, Chief Medical Officer (Age 48)
  • Jennifer Jarrett, Director (Age 46)
  • Scott H. Bice J.D., Independent Director (Age 74)
  • Jayson Dallas M.D., Independent Director (Age 49)
  • Oliver S. Fetzer Ph.D., Independent Director (Age 52)

Who owns Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.92%), Millennium Management LLC (2.03%), Renaissance Technologies LLC (1.44%), Teachers Advisors LLC (1.03%), Geode Capital Management LLC (0.89%) and Macquarie Group Ltd. (0.57%). Company insiders that own Arena Pharmaceuticals stock include Amit Munshi and Christine Anna White. View Institutional Ownership Trends for Arena Pharmaceuticals.

Who sold Arena Pharmaceuticals stock? Who is selling Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Hudson Bay Capital Management LP, BlackRock Inc., TIAA CREF Investment Management LLC, Two Sigma Advisers LP, Alliancebernstein L.P. and Metropolitan Life Insurance Co. NY. View Insider Buying and Selling for Arena Pharmaceuticals.

Who bought Arena Pharmaceuticals stock? Who is buying Arena Pharmaceuticals stock?

Arena Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Bailard Inc., Alps Advisors Inc., X Square Capital LLC, Schwab Charles Investment Management Inc., Teachers Advisors LLC, Macquarie Group Ltd. and American Century Companies Inc.. View Insider Buying and Selling for Arena Pharmaceuticals.

How do I buy Arena Pharmaceuticals stock?

Shares of Arena Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arena Pharmaceuticals' stock price today?

One share of Arena Pharmaceuticals stock can currently be purchased for approximately $39.97.

How big of a company is Arena Pharmaceuticals?

Arena Pharmaceuticals has a market capitalization of $1.60 billion and generates $123.97 million in revenue each year. The biopharmaceutical company earns $-22,510,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Arena Pharmaceuticals employs 106 workers across the globe.

How can I contact Arena Pharmaceuticals?

Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]


MarketBeat Community Rating for Arena Pharmaceuticals (ARNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  231 (Vote Underperform)
Total Votes:  441
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Arena Pharmaceuticals (NASDAQ:ARNA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.882.712.71
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $46.29$41.14$38.83$38.83
Price Target Upside: 13.45% upside21.44% upside54.78% upside82.75% upside

Arena Pharmaceuticals (NASDAQ:ARNA) Consensus Price Target History

Price Target History for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ:ARNA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/20/2018JMP SecuritiesBoost Price TargetOutperform$36.00 -> $63.00LowView Rating Details
1/17/2018Credit Suisse GroupInitiated CoverageOutperform -> Outperform$44.00LowView Rating Details
1/17/2018Leerink SwannReiterated RatingOutperform -> Positive$53.00 -> $56.00LowView Rating Details
1/17/2018Cantor FitzgeraldReiterated RatingBuy$45.00LowView Rating Details
1/3/2018Wells Fargo & CoUpgradeMarket Perform -> OutperformHighView Rating Details
8/8/2017Needham & Company LLCReiterated RatingHoldMediumView Rating Details
7/11/2017CitigroupBoost Price TargetBuy -> Buy$23.00 -> $37.00LowView Rating Details
3/16/2017FBR & CoReiterated RatingOutperform$60.00MediumView Rating Details
8/10/2016Jefferies GroupReiterated RatingBuyN/AView Rating Details
8/8/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
3/2/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
3/1/2016Royal Bank of CanadaReiterated RatingSector Perform$20.00 -> $15.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings History and Estimates Chart

Earnings by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.62)N/AView Earnings Details
11/7/2017Q3 2017($0.66)($0.65)$5.48 million$7.95 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.74)($0.77)$5.58 million$6.49 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.82)($0.90)$4.84 million$6.60 millionViewN/AView Earnings Details
3/14/2017Q4 2016($0.80)$1.60$14.12 million$85.40 millionViewN/AView Earnings Details
11/7/2016Q316($0.70)($0.50)$13.99 million$19.20 millionViewN/AView Earnings Details
8/8/2016Q216($1.00)($1.10)$10.44 million$9.50 millionViewN/AView Earnings Details
5/9/2016Q116($1.00)($0.90)$9.02 million$9.80 millionViewN/AView Earnings Details
2/29/2016Q415($1.30)($1.30)$8.26 million$7.80 millionViewN/AView Earnings Details
11/10/2015Q315($1.30)($1.10)$8.87 million$9.10 millionViewN/AView Earnings Details
8/5/2015Q215($1.40)($1.10)$10.95 million$9.18 millionViewN/AView Earnings Details
5/11/2015Q115($1.40)($1.00)$10.56 million$12.30 millionViewN/AView Earnings Details
3/2/2015Q414($1.20)($1.50)$10.36 million$9.20 millionViewN/AView Earnings Details
11/3/2014Q314($1.30)($0.50)$10.90 million$8.20 millionViewN/AView Earnings Details
8/1/2014Q2 14($1.10)($1.20)$9.81 million$12.80 millionViewN/AView Earnings Details
5/12/2014Q114($1.00)($1.20)$7.98 million$6.80 millionViewN/AView Earnings Details
2/27/2014Q413$0.20($1.10)$7.00 million$6.50 millionViewN/AView Earnings Details
11/7/2013Q313($1.20)($0.80)$5.30 million$3.60 millionViewN/AView Earnings Details
8/1/2013Q2 2013$1.50$1.80$57.30 million$68.90 millionViewN/AView Earnings Details
4/30/2013Q1 2013$1.10$0.90$50.36 million$2.37 millionViewN/AView Earnings Details
3/4/2013Q4 2012($0.30)($1.00)$21.94 million$1.94 millionViewN/AView Earnings Details
11/6/2012Q312($1.10)($0.70)$3.72 million$1.50 millionViewN/AView Earnings Details
8/9/2012($0.80)($1.20)ViewN/AView Earnings Details
5/1/2012Q1 2012($1.30)($1.54)ViewN/AView Earnings Details
3/14/2012Q4 2011($1.50)($1.62)ViewN/AView Earnings Details
11/9/2011($1.40)($1.60)ViewN/AView Earnings Details
8/9/2011($1.50)($1.60)ViewN/AView Earnings Details
5/10/2011($2.10)($3.50)ViewN/AView Earnings Details
3/11/2011($2.20)($2.30)ViewN/AView Earnings Details
11/9/2010Q3 2010($2.30)($3.09)ViewN/AView Earnings Details
8/3/2010Q2 2010($2.80)($2.76)ViewN/AView Earnings Details
5/7/2010Q1 2010($3.20)($3.30)ViewN/AView Earnings Details
3/12/2010Q4 2009($3.00)($3.76)ViewN/AView Earnings Details
11/9/2009Q3 2009($3.40)($3.83)ViewN/AView Earnings Details
8/3/2009Q2 2009($4.80)($4.80)ViewN/AView Earnings Details
5/11/2009Q1 2009($6.90)($6.82)ViewN/AView Earnings Details
3/12/2009Q4 2008($7.80)($8.44)ViewN/AView Earnings Details
10/30/2008Q3 2008($8.30)($7.60)ViewN/AView Earnings Details
8/5/2008Q2 2008($7.30)($8.92)ViewN/AView Earnings Details
5/7/2008Q1 2008($6.70)($7.47)ViewN/AView Earnings Details
2/27/2008Q4 2007($8.20)($5.98)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Arena Pharmaceuticals (NASDAQ:ARNA) Earnings Estimates

2018 EPS Consensus Estimate: ($2.92)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.72)($0.72)($0.72)
Q2 20181($0.72)($0.72)($0.72)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.74)($0.74)($0.74)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Arena Pharmaceuticals (NASDAQ:ARNA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.88%
Institutional Ownership Percentage: 71.02%
Insider Trades by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)
Institutional Ownership by Quarter for Arena Pharmaceuticals (NASDAQ:ARNA)

Arena Pharmaceuticals (NASDAQ ARNA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/12/2017Amit MunshiInsiderBuy25,000$1.19$29,750.0076,875View SEC Filing  
4/26/2017Amit MunshiInsiderBuy50,000$1.41$70,500.001,875View SEC Filing  
6/13/2016Christine Anna WhiteDirectorSell18,728$1.99$37,268.7285,529View SEC Filing  
3/30/2015Randall E WoodsDirectorSell76,268$4.49$342,443.32View SEC Filing  
3/17/2015Steven W SpectorEVPSell70,000$5.00$350,000.00View SEC Filing  
1/8/2015Steven W SpectorEVPSell45,000$6.26$281,700.00View SEC Filing  
1/7/2015William R Shanahan JrSVPSell50,000$5.49$274,500.00View SEC Filing  
7/1/2014Jack LiefCEOSell223,525$5.85$1,307,621.25View SEC Filing  
6/27/2014Donald D BelcherDirectorSell2,473$5.85$14,467.05View SEC Filing  
5/6/2014Donald BelcherDirectorSell4,176$7.00$29,232.0068,728View SEC Filing  
4/22/2014Harry Hixson, Jr.DirectorSell36,900$6.31$232,839.0082,876View SEC Filing  
4/14/2014Tina Susan NovaDirectorSell35,000$6.22$217,700.0018,728View SEC Filing  
4/1/2014Donald BelcherDirectorSell1,905$6.45$12,287.2568,728View SEC Filing  
4/1/2014William Shanahan, Jr.SVPSell60,000$6.37$382,200.0035,000View SEC Filing  
3/4/2014Steven SpectorEVPSell25,000$7.01$175,250.00101,794View SEC Filing  
1/17/2014Jack LiefCEOSell100,000$7.81$781,000.00583,704View SEC Filing  
1/10/2014Dominic BehanEVPSell33,332$6.25$208,325.00483,000View SEC Filing  
9/10/2013Dominic P BehanEVPSell200,000$6.31$1,262,000.00View SEC Filing  
9/5/2013Steven W SpectorEVPSell20,000$6.54$130,800.00View SEC Filing  
5/21/2013Craig Michael AudetSVPSell83,750$8.00$670,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Arena Pharmaceuticals (NASDAQ ARNA) News Headlines

Source:
DateHeadline
Assessing Chances Of Success For Arena Pharmaceuticals Highly Anticipated Etrasimod P2 Results - Seeking AlphaAssessing Chances Of Success For Arena Pharmaceutical's Highly Anticipated Etrasimod P2 Results - Seeking Alpha
seekingalpha.com - February 23 at 4:02 PM
Arena Pharmaceuticals (ARNA) Price Target Raised to $63.00Arena Pharmaceuticals (ARNA) Price Target Raised to $63.00
www.americanbankingnews.com - February 20 at 6:16 PM
Arena Pharmaceuticals Announces Changes to Board of Directors - PR Newswire (press release)Arena Pharmaceuticals Announces Changes to Board of Directors - PR Newswire (press release)
www.prnewswire.com - February 18 at 3:58 PM
Arena Pharmaceuticals (ARNA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - SlideshowArena Pharmaceuticals (ARNA) Presents At Leerink Partners 7th Annual Global Healthcare Conference - Slideshow
seekingalpha.com - February 16 at 4:01 PM
Arena Pharmaceuticals Announces Changes to Board of DirectorsArena Pharmaceuticals Announces Changes to Board of Directors
finance.yahoo.com - February 16 at 9:30 AM
Celgene's Future Growth Could Depend on a Competitor's Trial This QuarterCelgene's Future Growth Could Depend on a Competitor's Trial This Quarter
finance.yahoo.com - February 14 at 3:22 PM
Zacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $4.43 MillionZacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) Will Announce Quarterly Sales of $4.43 Million
www.americanbankingnews.com - February 12 at 4:32 AM
Arena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.64 Per ShareArena Pharmaceuticals, Inc. (ARNA) Expected to Post Earnings of -$0.64 Per Share
www.americanbankingnews.com - February 10 at 1:20 PM
Today’s Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUSToday’s Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS
finance.yahoo.com - February 9 at 3:26 PM
Arena Pharmaceuticals to Present at Upcoming Investor Conferences - PR Newswire (press release)Arena Pharmaceuticals to Present at Upcoming Investor Conferences - PR Newswire (press release)
www.prnewswire.com - February 8 at 5:48 AM
Arena Pharmaceuticals to Present at Upcoming Investor ConferencesArena Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 5:58 AM
Arena Pharmaceuticals (ARNA) Raised to "Hold" at ValuEngineArena Pharmaceuticals (ARNA) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - February 3 at 2:32 PM
Arena Pharmaceuticals Inc (NASDAQ:ARNA): Is Healthcare Attractive Relative To NasdaqGS Peers?Arena Pharmaceuticals Inc (NASDAQ:ARNA): Is Healthcare Attractive Relative To NasdaqGS Peers?
finance.yahoo.com - February 2 at 3:21 PM
Arena Pharmaceuticals, Inc. (ARNA) Given Consensus Rating of "Buy" by BrokeragesArena Pharmaceuticals, Inc. (ARNA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 2 at 12:35 PM
Arena Pharmaceuticals (ARNA) Rating Increased to Strong-Buy at BidaskClubArena Pharmaceuticals (ARNA) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - January 27 at 4:28 PM
$4.43 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter$4.43 Million in Sales Expected for Arena Pharmaceuticals, Inc. (ARNA) This Quarter
www.americanbankingnews.com - January 26 at 4:14 AM
Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases ... - PR Newswire (press release)Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases ... - PR Newswire (press release)
www.prnewswire.com - January 23 at 3:23 PM
Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York CityArena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City
finance.yahoo.com - January 23 at 9:18 AM
Arena Pharmaceuticals, Inc. (ARNA) to Post Q1 2018 Earnings of ($0.72) Per Share, Leerink Swann ForecastsArena Pharmaceuticals, Inc. (ARNA) to Post Q1 2018 Earnings of ($0.72) Per Share, Leerink Swann Forecasts
www.americanbankingnews.com - January 19 at 12:14 PM
Arena Gets $44 Price Target From Credit Suisse - Seeking AlphaArena Gets $44 Price Target From Credit Suisse - Seeking Alpha
seekingalpha.com - January 19 at 6:49 AM
Arena Pharmaceuticals: Significance Of This Quarters Catalysts - Seeking AlphaArena Pharmaceuticals: Significance Of This Quarter's Catalysts - Seeking Alpha
seekingalpha.com - January 19 at 6:49 AM
Surprising Analyst 12-Month Target For PBESurprising Analyst 12-Month Target For PBE
www.nasdaq.com - January 18 at 3:17 PM
Credit Suisse Group Initiates Coverage on Arena Pharmaceuticals (ARNA)Credit Suisse Group Initiates Coverage on Arena Pharmaceuticals (ARNA)
www.americanbankingnews.com - January 17 at 5:24 PM
Arena Pharmaceuticals: Binary Events On The Horizon - Seeking AlphaArena Pharmaceuticals: Binary Events On The Horizon - Seeking Alpha
seekingalpha.com - January 12 at 5:41 AM
Arena Pharmaceuticals (ARNA) CEO Amit Munshi Presents at 36th Annual JP Morgan Healthcare Conference ... - Seeking AlphaArena Pharmaceuticals (ARNA) CEO Amit Munshi Presents at 36th Annual JP Morgan Healthcare Conference ... - Seeking Alpha
seekingalpha.com - January 11 at 5:40 AM
FY2017 Earnings Forecast for Arena Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (ARNA)FY2017 Earnings Forecast for Arena Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (ARNA)
www.americanbankingnews.com - January 10 at 8:00 AM
Arena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from AnalystsArena Pharmaceuticals, Inc. (ARNA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 8 at 8:38 AM
 Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.64 EPS Brokerages Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Announce -$0.64 EPS
www.americanbankingnews.com - January 7 at 11:24 AM
Arena Pharmaceuticals Makes A Run On Upgrade - Can It Hold? - Seeking AlphaArena Pharmaceuticals Makes A Run On Upgrade - Can It Hold? - Seeking Alpha
seekingalpha.com - January 6 at 3:16 PM
Bloomberg Markets: Fed Backs Hikes, Terrific Year for AutosBloomberg Markets: Fed Backs Hikes, Terrific Year for Autos
www.bloomberg.com - January 5 at 3:18 PM
TODAY'S CHARTS: MoneyGram plunges on blocked deal; IBM gets an upgrade; AMD soars on Intel 'design flaw'TODAY'S CHARTS: MoneyGram plunges on blocked deal; IBM gets an upgrade; AMD soars on Intel 'design flaw'
finance.yahoo.com - January 5 at 3:18 PM
30 Stocks Moving In Wednesdays Mid-Day Session | Benzinga - Benzinga30 Stocks Moving In Wednesday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - January 4 at 5:37 AM
Arena Pharma Upgraded Ahead Of Clinical Data Release - BenzingaArena Pharma Upgraded Ahead Of Clinical Data Release - Benzinga
www.benzinga.com - January 4 at 5:37 AM
Arena Pharmaceuticals (ARNA) Upgraded to "Strong-Buy" by BidaskClubArena Pharmaceuticals (ARNA) Upgraded to "Strong-Buy" by BidaskClub
www.americanbankingnews.com - December 27 at 9:44 PM
Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Arena Pharmaceuticals, Inc. :ARNA-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 3:51 PM
BidaskClub Lowers Arena Pharmaceuticals (ARNA) to BuyBidaskClub Lowers Arena Pharmaceuticals (ARNA) to Buy
www.americanbankingnews.com - December 24 at 12:28 PM
Arena Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference on January 10 - PR Newswire (press release)Arena Pharmaceuticals to Present at the 36th Annual JP Morgan Healthcare Conference on January 10 - PR Newswire (press release)
www.prnewswire.com - December 22 at 5:54 AM
Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10Arena Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 10
finance.yahoo.com - December 21 at 3:16 PM
Does Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) 67.6% EPS Growth Reflect The Long-Term Trend?Does Arena Pharmaceuticals Inc’s (NASDAQ:ARNA) 67.6% EPS Growth Reflect The Long-Term Trend?
finance.yahoo.com - December 19 at 5:52 AM
Arena Pharmaceuticals, Inc. (ARNA) Given Average Rating of "Buy" by BrokeragesArena Pharmaceuticals, Inc. (ARNA) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 14 at 8:42 AM
Arena Pharma Races Toward Q1 2018 Trial Results - Seeking Alpha - Seeking AlphaArena Pharma Races Toward Q1 2018 Trial Results - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 12 at 5:50 AM
Here's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in NovemberHere's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
finance.yahoo.com - December 11 at 3:16 PM
Heres What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in NovemberHere's What Pushed Arena Pharmaceuticals, Inc. Up 10.6% in November
www.fool.com - December 11 at 11:54 AM
Arena Pharmaceuticals, Inc. (ARNA) Expected to Announce Quarterly Sales of $4.43 MillionArena Pharmaceuticals, Inc. (ARNA) Expected to Announce Quarterly Sales of $4.43 Million
www.americanbankingnews.com - December 6 at 9:50 AM
Arena Pharma (ARNA) and Everest Medicines Enter Pact for ... - StreetInsider.comArena Pharma (ARNA) and Everest Medicines Enter Pact for ... - StreetInsider.com
www.streetinsider.com - December 5 at 3:17 PM
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in ChinaArena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
finance.yahoo.com - December 5 at 3:17 PM
Zacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.64 EPSZacks: Analysts Anticipate Arena Pharmaceuticals, Inc. (ARNA) to Post -$0.64 EPS
www.americanbankingnews.com - December 4 at 8:44 AM
Market Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International — Emerging Consolidated Expectations, Analyst RatingsMarket Trends Toward New Normal in Arena Pharmaceuticals, National Fuel Gas, Capitol Federal Financial, Comfort Systems, National Instruments, and Navistar International — Emerging Consolidated Expectations, Analyst Ratings
finance.yahoo.com - November 27 at 2:06 PM
Financial Contrast: Arena Pharmaceuticals (ARNA) and Sunesis Pharmaceuticals (SNSS)Financial Contrast: Arena Pharmaceuticals (ARNA) and Sunesis Pharmaceuticals (SNSS)
www.americanbankingnews.com - November 23 at 3:12 PM
Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23?Should You Buy Arena Pharmaceuticals Inc (ARNA) At $27.23?
finance.yahoo.com - November 22 at 4:40 PM

SEC Filings

Arena Pharmaceuticals (NASDAQ:ARNA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Arena Pharmaceuticals (NASDAQ:ARNA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Arena Pharmaceuticals (NASDAQ ARNA) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.